Isolagen, Inc. announced today that Declan Daly, Chief Executive Officer, will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 3:30 p.m. (EST) at Le Parker Meridien hotel in New York, New York.
The presentation will be webcast live and can be accessed on the Isolagen website, www.isolagen.com, on the investors page. A replay will be available approximately three hours after the presentation and will be archived on the company's website for 90 days.
About Isolagen, Inc.
Isolagen(TM), Inc. (Amex: ILE - News) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera® Laboratories, Inc.
Source: Isolagen, Inc.
The presentation will be webcast live and can be accessed on the Isolagen website, www.isolagen.com, on the investors page. A replay will be available approximately three hours after the presentation and will be archived on the company's website for 90 days.
About Isolagen, Inc.
Isolagen(TM), Inc. (Amex: ILE - News) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera® Laboratories, Inc.
Source: Isolagen, Inc.
0 comments:
Post a Comment